Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AUA 2022 | Mechanism of action of the adenovirus oncolytic virus CG0070 plus pembrolizumab in bladder cancer

Roger Li • 23 May 2022
AUA 2022
Bladder Cancer Genitourinary Cancer Antibodies CG0070 Pembrolizumab

Roger Li, MD, Moffitt Cancer Center, Tampa, FL, explains the mechanism of action of CG0070, an adenovirus oncolytic virus, and the rationale behind combining it with pembrolizumab to treat Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer. This interview took place at the American Urological Association annual congress 2022 in New Orleans and online.

Disclosures

Research support: Predicine; Decipher Biosciences. CG Oncology.
Clinical trial protocol committee – CG Oncology;
Scientific advisor/consultant – BMS, Ferring, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence.

More from Roger Li

2:08
CORE1 trial: CG0070 plus pembrolizumab for BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
1:55
Durvalumab monotherapy for patients with BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals